Differential tumor-targeting abilities of three single-domain antibody formats

Autor: Shenghua Li, Maria L. Jaramillo, Yves Durocher, Jason Baardsnes, Jianbing Zhang, Toya Nath Baral, Roger MacKenzie, Maureen D. O'Connor-McCourt, Mehdi Arbabi-Ghahroudi, Zheng J. Wang, Ulrike Trojahn, Tingtung A. Chang, Andrea Bell
Rok vydání: 2010
Předmět:
Zdroj: Cancer Letters. 289:81-90
ISSN: 0304-3835
DOI: 10.1016/j.canlet.2009.08.003
Popis: The large molecular size of antibody drugs is considered one major factor preventing them from becoming more efficient therapeutics. Variable regions of heavy chain antibodies (HCAbs), or single-domain antibodies (sdAbs), are ideal building blocks for smaller antibodies due to their molecular size and enhanced stability. In the search for better antibody formats for in vivo imaging and/or therapy of cancer, three types of sdAb-based molecules directed against epidermal growth factor receptor (EGFR) were constructed, characterized and tested. Eleven sdAbs were isolated from a phage display library constructed from the sdAb repertoire of a llama immunized with a variant of EGFR. A pentameric sdAb, or pentabody, V2C-EG2 was constructed by fusing one of the sdAbs, EG2, to a pentamerization protein domain. A chimeric HCAb (cHCAb), EG2-hFc, was constructed by fusing EG2 to the fragment crystallizable (Fc) of human IgG1. Whereas EG2 and V2C-EG2 localized mainly in the kidneys after i.v. injection, EG2-hFc exhibited excellent tumor accumulation, and this was largely attributed to its long serum half life, which is comparable to that of IgGs. The moderate size (∼80 kDa) and intact human Fc make HCAbs a unique antibody format which may outperform whole IgGs as imaging and therapeutic reagents.
Databáze: OpenAIRE